N511 Module 8 assignment: 22-slide medication review of the five ShadowHealth focused exams, a full sample

Five Focused Exams, One Prescriber's Review: Mechanisms, Pharmacokinetics, Alternatives, and Guidelines for the Drugs Chosen in N511

Student Name

Master of Science in Nursing Program, Aspen University

N511: Advanced Pharmacology

Instructor Name

Month Day, Year

Slide 2: Purpose and Approach

Review every drug chosen across the five ShadowHealth focused exams

For each: mechanism, pharmacokinetics, alternatives, guideline basis

Close with safety themes that cut across all five cases

Speaker notes: This presentation looks back at the drugs I selected in the five focused exams this term: urinary tract infection, community-acquired pneumonia, COPD, hypertension with type 2 diabetes, and pain management. For each drug I review how it works, how the body handles it, what I would use instead, and which guideline supports the choice. The last slides pull out the safety lessons that appeared in more than one case.

Slide 3: The Five Cases at a Glance

UTI: older woman on an ACE inhibitor and spironolactone, eGFR near 50

Pneumonia: outpatient with diabetes on citalopram

COPD: rising rescue inhaler use, eosinophils 150

Hypertension and diabetes: gout history, albuminuria

Pain: knee osteoarthritis, reduced kidney function

Speaker notes: Each virtual patient had a detail beyond the diagnosis that changed the prescription. Kidney function mattered in three of the five cases, interacting medications in four, and a practical factor such as hand strength in one. Keeping those details in view explains why the choices on the following slides are not always the most familiar ones.

Slide 4: Nitrofurantoin, Mechanism and Pharmacokinetics

Reduced by bacterial flavoproteins to reactive intermediates

Attacks several bacterial targets at once, so resistance develops slowly

Short plasma half-life, high urinary concentration

Absorption improved by food; macrocrystal form slows absorption

Speaker notes: Nitrofurantoin is activated inside bacteria, where enzymes turn it into reactive compounds that damage multiple targets at the same time. Because several mutations would be needed to escape it, resistance has stayed low for decades. It leaves the blood quickly and concentrates in the urine, which is exactly where cystitis needs it, and taking it with food improves absorption and tolerance.

Slide 5: Cystitis Alternatives and Guideline Basis

First line: nitrofurantoin for 5 days (Gupta et al., 2011)

Fosfomycin 3 g once: convenient, less effective in a trial

Trimethoprim-sulfamethoxazole: only if resistance under about 20 percent and no potassium risk

Fluoroquinolones reserved for more serious infections

Speaker notes: The international cystitis guideline lists nitrofurantoin, trimethoprim-sulfamethoxazole where resistance is low, fosfomycin, and pivmecillinam as first-line options. In a randomized trial, five days of nitrofurantoin produced higher clinical resolution than single-dose fosfomycin, 70 versus 58 percent at 28 days (Huttner et al., 2018). For my patient, trimethoprim was ruled out because it raises potassium, a danger alongside her ACE inhibitor and spironolactone.

Slide 6: Amoxicillin-Clavulanate, Mechanism and Pharmacokinetics

Amoxicillin blocks peptidoglycan cross-linking, causing lysis

Clavulanate inactivates beta-lactamase enzymes

Well absorbed orally; amoxicillin cleared mainly by the kidneys

Killing depends on time above the inhibitory concentration

Speaker notes: Amoxicillin binds penicillin-binding proteins and stops bacteria from building their cell walls. Clavulanate has little antibacterial action of its own but protects amoxicillin from the beta-lactamase enzymes made by Haemophilus and Moraxella. Amoxicillin is cleared by the kidneys and needs dose adjustment only when function is severely reduced. Because its effect depends on how long levels stay above the organism's threshold, regular dosing intervals matter.

Slide 7: Doxycycline, Mechanism and Pharmacokinetics

Binds the 30S ribosomal subunit and halts protein synthesis

Reaches intracellular organisms: Mycoplasma, Legionella, Chlamydophila

Nearly complete oral absorption, long half-life, twice-daily dosing

No renal dose change; chelated by calcium, magnesium, iron

Speaker notes: Doxycycline adds coverage for atypical organisms that lack a cell wall or live inside host cells, which beta-lactams cannot reach. It is almost fully absorbed and has a long half-life, and it is cleared partly through the gut, so kidney function does not change the dose. Its main practical interactions are with antacids, dairy, and iron, which bind it and should be separated by a couple of hours.

Slide 8: Pneumonia Alternatives and Guideline Basis

Outpatient with comorbidity: beta-lactam plus macrolide or doxycycline, or respiratory fluoroquinolone alone (Metlay et al., 2019)

Cephalosporin such as cefpodoxime can replace the beta-lactam

Azithromycin and levofloxacin avoided here because of QT prolongation with citalopram

Minimum 5 days and until clinically stable

Speaker notes: The ATS/IDSA guideline defines comorbidities, including diabetes, that call for broader outpatient coverage and offers either combination therapy or fluoroquinolone monotherapy (Metlay et al., 2019). My patient's citalopram already lengthened his QT interval, so both azithromycin and levofloxacin carried added arrhythmia risk. Doxycycline gave atypical coverage without that risk, and the guideline supports a minimum of five days.

Slide 9: Tiotropium, Mechanism and Pharmacokinetics

Long-acting muscarinic antagonist at airway M3 receptors

Blocks acetylcholine-driven bronchoconstriction and mucus secretion

Slow dissociation from M3 receptors allows once-daily dosing

Small systemic dose, cleared mainly by the kidneys

Speaker notes: Tiotropium blocks muscarinic M3 receptors on airway smooth muscle, removing the cholinergic tone that narrows airways in COPD. It lets go of M3 receptors slowly, which gives a 24-hour effect from one daily dose. Only a small amount reaches the bloodstream after inhalation, and what does is cleared mostly by the kidneys, so patients with significant kidney impairment need closer watching for anticholinergic effects.

Slide 10: Olodaterol, Mechanism and Pharmacokinetics

Long-acting beta-2 agonist

Raises cyclic AMP in airway smooth muscle, causing relaxation

24-hour duration from once-daily inhalation

Hepatic metabolism; tremor and palpitations at higher exposure

Speaker notes: Olodaterol stimulates beta-2 receptors, raising cyclic AMP inside airway smooth muscle cells and relaxing them. Its long duration allows it to be paired with tiotropium in one once-daily device. Combining two bronchodilators with different mechanisms improves lung function and symptoms more than either alone. Systemic effects such as tremor and palpitations are uncommon at inhaled doses.

Slide 11: COPD Alternatives and Guideline Basis

Group B: LAMA plus LABA recommended (Agustí et al., 2023)

Inhaled corticosteroid mainly for frequent exacerbations with eosinophils of 300 or more

LABA plus ICS without a LAMA no longer encouraged

Device selection is part of the prescription

Speaker notes: GOLD 2023 recommends dual long-acting bronchodilators for patients with high symptoms and few exacerbations (Agustí et al., 2023). An inhaled corticosteroid adds pneumonia risk and helps mainly those with frequent exacerbations and high blood eosinophils, so my patient with a count of 150 did not receive one. I chose a soft mist device because her arthritic hands and weak inhalation made other devices hard to use correctly.

Slide 12: Losartan, Mechanism and Pharmacokinetics

Blocks angiotensin II at the AT1 receptor: vasodilation, less aldosterone

Converted by CYP2C9 and CYP3A4 to a more potent active metabolite

Mild uricosuric effect unique among ARBs

Monitor potassium and creatinine after starting

Speaker notes: Losartan blocks the AT1 receptor, lowering vascular resistance and aldosterone release. Part of its effect comes from an active metabolite formed in the liver, which lasts longer than the parent drug. Unlike other angiotensin receptor blockers, losartan also increases uric acid excretion, which made it the preferred choice for a patient with gout. Potassium and creatinine should be checked within a few weeks of starting.

Slide 13: Amlodipine, Mechanism and Pharmacokinetics

Dihydropyridine calcium channel blocker

Blocks L-type channels in arterial smooth muscle

Very long half-life: steady once-daily effect

Metabolized by CYP3A4; ankle edema is dose-related

Speaker notes: Amlodipine blocks calcium entry into arterial smooth muscle, relaxing arteries and lowering blood pressure with little effect on heart rate or conduction. Its half-life of more than a day produces smooth control and forgives a missed dose. Hepatic CYP3A4 handles its metabolism, which means drugs that block that enzyme push its levels up. Ankle swelling, the most common complaint, comes from arteriolar dilation and is not a sign of fluid overload.

Slide 14: Metformin, Mechanism and Pharmacokinetics

Reduces hepatic glucose production and improves insulin sensitivity

Not metabolized; excreted unchanged by the kidneys

Do not start at eGFR 30 to 45; stop below 30

Long-term use can lower vitamin B12

Speaker notes: Metformin lowers blood glucose mainly by reducing glucose output from the liver, without causing hypoglycemia on its own. It is not metabolized and the kidneys excrete it intact, so kidney function determines whether it can be used and at what dose. Long-term users should have vitamin B12 checked periodically, particularly if they develop neuropathy.

Slide 15: SGLT2 Inhibitors, Mechanism and Pharmacokinetics

Block sodium-glucose cotransporter 2 in the proximal tubule

Glucose and sodium lost in urine; lower pressure inside the glomerulus

Glucose lowering fades as eGFR falls; kidney and heart benefits persist

Risks: genital fungal infections, volume depletion, euglycemic ketoacidosis

Speaker notes: SGLT2 inhibitors block glucose reabsorption in the proximal tubule. The extra sodium reaching the distal nephron restores the signal that constricts the afferent arteriole, lowering pressure in the glomerulus and protecting the kidney. That is why they are chosen for patients with albuminuric kidney disease even when their glucose-lowering effect is modest. They are cleared mainly by hepatic glucuronidation, and patients should pause them during acute illness or before surgery.

Slide 16: Hypertension and Diabetes, Alternatives and Guidelines

Two first-line agents when more than 20/10 above goal (Whelton et al., 2018)

ACE inhibitor as alternative to ARB; thiazide avoided with gout

SGLT2 inhibitor or GLP-1 receptor agonist chosen for organ protection (ElSayed et al., 2023)

Sulfonylureas cheaper but carry hypoglycemia and weight gain

Speaker notes: The blood pressure guideline supports starting two drugs of different classes when readings are well above goal (Whelton et al., 2018). The diabetes standards recommend choosing agents with proven kidney or cardiovascular benefit for patients with chronic kidney disease or heart disease, regardless of the starting A1C (ElSayed et al., 2023). Cheaper options remain reasonable when cost prevents access, as long as their risks are managed.

Slide 17: Topical Diclofenac, Mechanism and Pharmacokinetics

Inhibits COX-1 and COX-2 in tissue near the joint

Systemic exposure a small fraction of oral dosing

Lower risk of kidney and gastrointestinal harm

Local skin irritation is the main adverse effect

Speaker notes: Diclofenac gel inhibits the cyclooxygenase enzymes that produce inflammatory prostaglandins, but it acts mainly in the tissues around the knee. Blood levels after topical use are far lower than after oral dosing, which is why it suits an older adult with reduced kidney function who also takes an ACE inhibitor and a diuretic. The osteoarthritis guideline strongly recommends it for the knee (Kolasinski et al., 2020).

Slide 18: Acetaminophen and Other Pain Options

Acetaminophen: central analgesic, hepatic conjugation, small toxic fraction via CYP2E1

Cap daily dose in older adults and with alcohol use or liver disease

Duloxetine and tramadol conditionally recommended; other opioids not advised

Exercise and weight loss strongly recommended

Speaker notes: Acetaminophen acts centrally and is cleared by conjugation in the liver. A small portion forms a toxic metabolite that glutathione normally neutralizes, which is why the daily dose is limited, especially in older adults and those who drink alcohol. The guideline ranks duloxetine and tramadol as conditional options and advises against other opioids, and it strongly recommends exercise and weight loss, which often help more than any drug (Kolasinski et al., 2020).

Slide 19: Safety Themes Across All Five Cases

Estimate kidney function before choosing a drug

Check every new drug against the full list, including over-the-counter products

Watch for additive effects: potassium, QT, kidney perfusion

Confirm the patient can take the drug as intended

Speaker notes: Looking across the five exams, the most important decisions came from the patient's other drugs and organs, not the diagnosis. Potassium, the QT interval, and kidney perfusion each appeared as additive risks. Over-the-counter ibuprofen and sleep aids mattered as much as prescriptions. And an inhaler or a regimen only works if the patient can use it correctly and afford it.

Slide 20: Implications for Advanced Practice

Pharmacology is individualized reasoning, not recall

Document why a guideline default was changed

Teach with teach-back; schedule the follow-up that proves the drug worked

Revisit each regimen as kidney function and medication lists change

Speaker notes: As a future advanced practice nurse, I will write down the reason whenever I depart from a guideline's usual choice, so the next clinician understands it. I will schedule monitoring that answers a specific question, such as whether potassium stayed safe or whether rescue inhaler use fell. And I will treat each regimen as provisional, to be revisited as the patient's kidneys, weight, and other drugs change.

Slide 21: Conclusion

Five cases, eleven drugs, one habit: read the whole patient

Mechanism explains benefit and harm alike

Guidelines set the default; the patient sets the final choice

Speaker notes: The drugs reviewed here work in very different ways, but the same understanding of mechanism explains both why they help and how they can harm. Guidelines give a reliable starting point, and the details of each patient decide the final prescription. Reading the whole patient, not only the diagnosis, was the lesson of every focused exam this term.

References

Agustí, A., Celli, B. R., Criner, G. J., Halpin, D., Anzueto, A., Barnes, P., Bourbeau, J., Han, M. K., Martinez, F. J., Montes de Oca, M., Mortimer, K., Papi, A., Pavord, I., Roche, N., Salvi, S., Sin, D. D., Singh, D., Stockley, R., López Varela, M. V., ... Vogelmeier, C. F. (2023). Global Initiative for Chronic Obstructive Lung Disease 2023 report: GOLD executive summary. European Respiratory Journal, 61(4), Article 2300239. https://doi.org/10.1183/13993003.00239-2023

ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Leon, J., Lyons, S. K., Perry, M. L., Prahalad, P., Pratley, R. E., Seley, J. J., Stanton, R. C., & Gabbay, R. A. (2023). 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes, 2023. Diabetes Care, 46(Suppl. 1), S140-S157. https://doi.org/10.2337/dc23-S009

Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., Moran, G. J., Nicolle, L. E., Raz, R., Schaeffer, A. J., & Soper, D. E. (2011). International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clinical Infectious Diseases, 52(5), e103-e120. https://doi.org/10.1093/cid/ciq257

Huttner, A., Kowalczyk, A., Turjeman, A., Babich, T., Brossier, C., Eliakim-Raz, N., Kosiek, K., Martinez de Tejada, B., Roux, X., Shiber, S., Theuretzbacher, U., von Dach, E., Yahav, D., Leibovici, L., Godycki-Cwirko, M., Mouton, J. W., & Harbarth, S. (2018). Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: A randomized clinical trial. JAMA, 319(17), 1781-1789. https://doi.org/10.1001/jama.2018.3627

Kolasinski, S. L., Neogi, T., Hochberg, M. C., Oatis, C., Guyatt, G., Block, J., Callahan, L., Copenhaver, C., Dodge, C., Felson, D., Gellar, K., Harvey, W. F., Hawker, G., Herzig, E., Kwoh, C. K., Nelson, A. E., Samuels, J., Scanzello, C., White, D., ... Reston, J. (2020). 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis & Rheumatology, 72(2), 220-233. https://doi.org/10.1002/art.41142

Metlay, J. P., Waterer, G. W., Long, A. C., Anzueto, A., Brozek, J., Crothers, K., Cooley, L. A., Dean, N. C., Fine, M. J., Flanders, S. A., Griffin, M. R., Metersky, M. L., Musher, D. M., Restrepo, M. I., & Whitney, C. G. (2019). Diagnosis and treatment of adults with community-acquired pneumonia: An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. American Journal of Respiratory and Critical Care Medicine, 200(7), e45-e67. https://doi.org/10.1164/rccm.201908-1581ST

Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., MacLaughlin, E. J., Muntner, P., Ovbiagele, B., Smith, S. C., Spencer, C. C., Stafford, R. S., Taler, S. J., Thomas, R. J., Williams, K. A., ... Wright, J. T. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Journal of the American College of Cardiology, 71(19), e127-e248. https://doi.org/10.1016/j.jacc.2017.11.006